Bluestone JA - Search Results

1

Next-generation regulatory T cell therapy.

Ferreira LMR, Muller YD, Bluestone JA, Tang Q. Ferreira LMR, et al. Among authors: bluestone ja. Nat Rev Drug Discov. 2019 Oct;18(10):749-769. doi: 10.1038/s41573-019-0041-4. Epub 2019 Sep 20. Nat Rev Drug Discov. 2019. PMID: 31541224 Free PMC article. Review.

2

The Src family kinase Fyn mediates signals induced by TCR antagonists.

Tang Q, Subudhi SK, Henriksen KJ, Long CG, Vives F, Bluestone JA. Tang Q, et al. Among authors: bluestone ja. J Immunol. 2002 May 1;168(9):4480-7. doi: 10.4049/jimmunol.168.9.4480. J Immunol. 2002. PMID: 11970992

3

CTLA-4 regulates the requirement for cytokine-induced signals in T(H)2 lineage commitment.

Bour-Jordan H, Grogan JL, Tang Q, Auger JA, Locksley RM, Bluestone JA. Bour-Jordan H, et al. Among authors: bluestone ja. Nat Immunol. 2003 Feb;4(2):182-8. doi: 10.1038/ni884. Epub 2003 Jan 13. Nat Immunol. 2003. PMID: 12524538

4

Natural versus adaptive regulatory T cells.

Bluestone JA, Abbas AK. Bluestone JA, et al. Nat Rev Immunol. 2003 Mar;3(3):253-7. doi: 10.1038/nri1032. Nat Rev Immunol. 2003. PMID: 12658273 Review.

5

Regulatory T-cell therapy: is it ready for the clinic?

Bluestone JA. Bluestone JA. Nat Rev Immunol. 2005 Apr;5(4):343-9. doi: 10.1038/nri1574. Nat Rev Immunol. 2005. PMID: 15775994 Review.

6

Clinical application of regulatory T cells for treatment of type 1 diabetes and transplantation.

Brusko T, Bluestone J. Brusko T, et al. Eur J Immunol. 2008 Apr;38(4):931-4. doi: 10.1002/eji.200738108. Eur J Immunol. 2008. PMID: 18395864 Free article.

7

IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells.

Grinberg-Bleyer Y, Baeyens A, You S, Elhage R, Fourcade G, Gregoire S, Cagnard N, Carpentier W, Tang Q, Bluestone J, Chatenoud L, Klatzmann D, Salomon BL, Piaggio E. Grinberg-Bleyer Y, et al. J Exp Med. 2010 Aug 30;207(9):1871-8. doi: 10.1084/jem.20100209. Epub 2010 Aug 2. J Exp Med. 2010. PMID: 20679400 Free PMC article.

8

The Immune Tolerance Network at 10 years: tolerance research at the bedside.

Bluestone JA, Auchincloss H, Nepom GT, Rotrosen D, St Clair EW, Turka LA. Bluestone JA, et al. Nat Rev Immunol. 2010 Nov;10(11):797-803. doi: 10.1038/nri2869. Nat Rev Immunol. 2010. PMID: 20972473 Review.

9

The chromatin-modifying enzyme Ezh2 is critical for the maintenance of regulatory T cell identity after activation.

DuPage M, Chopra G, Quiros J, Rosenthal WL, Morar MM, Holohan D, Zhang R, Turka L, Marson A, Bluestone JA. DuPage M, et al. Among authors: bluestone ja. Immunity. 2015 Feb 17;42(2):227-238. doi: 10.1016/j.immuni.2015.01.007. Epub 2015 Feb 10. Immunity. 2015. PMID: 25680271 Free PMC article.

10

Targeting Treg signaling for the treatment of autoimmune diseases.

Spence A, Klementowicz JE, Bluestone JA, Tang Q. Spence A, et al. Among authors: bluestone ja. Curr Opin Immunol. 2015 Dec;37:11-20. doi: 10.1016/j.coi.2015.09.002. Epub 2015 Sep 29. Curr Opin Immunol. 2015. PMID: 26432763 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

535 results

Search Page